– November 1, 2007
November 1, 2007
View Issues
-
Prognostic Value of CRP in Renal Cancer
C-reactive protein, an acute phase reactant, is shown to offer significant prognostic information for post nephrectomy patients with renal cell carcinoma. The value of this information will be enhanced if future studies indicate that patients with high levels are more likely to benefit from adjuvant therapy or if it turns out to be a sensitive marker of recurrent disease. -
CHOP-Campath for PTCL
This multicenter trial evaluated the efficacy of combining alemtuzumab (Campath 1-H) to standard CHOP for peripheral T-cell lymphomas. Among 24 evaluable patients, the complete response rate was 17/24 (71%) using 8 cycles of CHOP plus 30 mg of Campath monthly. -
Low Dose Oral Chemotherapy for Indolent NHL in Elderly Patients
Oral fludarabine and cyclophosphamide were used in combination for initial treatment of non-Hodgkin lymphoma in 25 elderly patients. During an observation period of just over 3 years, 84% were responsive to treatment and there was an overall survival rate of 70%. -
Venous Thromboembolism and Prognosis in Pancreatic Cancer
In a careful analysis of 227 patients with unresectable or metastatic pancreatic carcinoma treated on protocol with chemotherapy, the development of venous thromboembolism (VTE) was associated with shorter progression-free and overall survival. -
Examining The Range of Therapy for Elderly Patients with Hematological Malignancy
The management of acute myelogenous leukemia in elderly patients has been challenging and there has developed a pervasive pessimism about the role of chemotherapy in management. Two recent reports may counter this with demonstration of a benefit for induction chemotherapy and, in selected cases, both efficacy and safety of stem cell transplantation using nonmyeloablative conditioning. -
Pharmacology Watch
Are thiazolidinediones safe? New study shows Zometa reduces risk of hip fractures and improves survival; Merck HIV vaccine proven ineffective in clinical trials; no causal association found between exposure to mercury from thimerosal; and FDA approvals. -
Clinical Briefs in Primary Care Supplement